Total Payments
$533,501
2024 Payments
$310,335
Companies
8
Transactions
77
Payment Breakdown by Category
Research$506,128 (94.9%)
Consulting$19,602 (3.7%)
Travel$6,344 (1.2%)
Food & Beverage$1,426 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $506,128 | 36 | 94.9% |
| Consulting Fee | $19,602 | 7 | 3.7% |
| Travel and Lodging | $6,344 | 14 | 1.2% |
| Food and Beverage | $1,426 | 20 | 0.3% |
Payments by Type
Research
$506,128
36 transactions
General
$27,373
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $503,257 | 57 | $0 (2024) |
| RECORDATI_RARE_DISEASES_INC. | $25,268 | 11 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $2,352 | 2 | $0 (2022) |
| PFIZER INC. | $1,341 | 3 | $0 (2024) |
| IBSA Pharma Inc. | $1,000 | 1 | $0 (2020) |
| Tandem Diabetes Care, Inc. | $125.00 | 1 | $0 (2023) |
| Eton Pharmaceuticals, Inc. | $123.63 | 1 | $0 (2024) |
| Lilly USA, LLC | $34.13 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $310,335 | 44 | Neurocrine Biosciences, Inc. ($283,635) |
| 2023 | $219,814 | 30 | Neurocrine Biosciences, Inc. ($219,622) |
| 2022 | $1,372 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($1,372) |
| 2020 | $1,980 | 2 | IBSA Pharma Inc. ($1,000) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | PFIZER INC. | GENOTROPIN (Drug) | Travel and Lodging | In-kind items and services | $798.27 | General |
| Category: ENDOCRINE DISEASE | ||||||
| 12/13/2024 | PFIZER INC. | GENOTROPIN (Drug) | Travel and Lodging | In-kind items and services | $509.00 | General |
| Category: ENDOCRINE DISEASE | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 12/09/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $6,338.98 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 11/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $30,289.01 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 11/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $15,244.08 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 10/25/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $183.00 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/25/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $135.75 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/25/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $40.61 | General |
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $9,144.00 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $5,120.50 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $3,633.50 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $2,048.00 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $1,829.00 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $1,126.50 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $768.00 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $731.50 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $548.50 | Research |
| Study: CLCI699C2203 • Category: ENDOCRINE AGENT | ||||||
| 09/16/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $20,567.33 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 09/16/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| 09/16/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $2,022.85 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 09/16/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $74.00 | General |
| 09/16/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $18.13 | General |
| 09/16/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $18.09 | General |
| 09/07/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $215.46 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences Inc. | $220,639 | 8 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences, Inc. | $208,348 | 14 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine BioSciences Inc. | $51,872 | 3 |
| CLCI699C2203 | RECORDATI_RARE_DISEASES_INC. | $25,268 | 11 |
About Dr. Maya Lodish, M.D
Dr. Maya Lodish, M.D is a Pediatric Endocrinology healthcare provider based in Bethesda, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1750401824.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maya Lodish, M.D has received a total of $533,501 in payments from pharmaceutical and medical device companies, with $310,335 received in 2024. These payments were reported across 77 transactions from 8 companies. The most common payment nature is "" ($506,128).
Ad
Practice Information
- Specialty Pediatric Endocrinology
- Location Bethesda, MD
- Active Since 03/30/2007
- Last Updated 07/08/2007
- Taxonomy Code 2080P0205X
- Entity Type Individual
- NPI Number 1750401824
Products in Payments
- OSILODROSTAT (Drug) $25,268
- Vitrakvi (Drug) $2,352
- GENOTROPIN (Drug) $1,341
- Tirosint (Drug) $1,000
- t:slim X2 Insulin Pump with Control-IQ (Device) $125.00
- ALKINDI (Drug) $123.63
- RETEVMO (Drug) $34.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Endocrinology Doctors in Bethesda
Dr. Mary Roberts, Md, MD
Pediatric Endocrinology — Payments: $6,163
Pediatric Endocrinology $6,163
Christina Tatsi, M.d, M.D
Pediatric Endocrinology — Payments: $1,400
Pediatric Endocrinology $1,400
Dr. Noelle Larson, Md, MD
Pediatric Endocrinology — Payments: $1,094
Pediatric Endocrinology $1,094
Dr. Jack Yanovski, Md, Phd, MD, PHD
Pediatric Endocrinology — Payments: $192.24
Pediatric Endocrinology $192.24
Dr. Rachael Paz, M.d, M.D
Pediatric Endocrinology — Payments: $181.79
Pediatric Endocrinology $181.79
Dr. Chelsi Flippo, Md, MD
Pediatric Endocrinology — Payments: $157.25
Pediatric Endocrinology $157.25